Top Abstract Purchase Related
Home
>
Node
>
Subnode

Resistance to EGFR targeting therapies in lung cancer

Watzka, S.B.; Posch, F.; Hochmair, M.; Setinek, U.; Köstler, W.J.; Müller, M.R.

Minerva Chirurgica 66(5): 483-494

2011

ISSN/ISBN: 0026-4733
PMID: 22117213
Document Number: 650885
The treatment of advanced non-small cell lung cancer (NSCLC) by therapies targeting the epidermal growth factor receptor (EGFR) pathway represents one of the most important advances in thoracic oncology. Reversible EGFR tyrosine kinase inhibitors (TKIs), like gefitinib and erlotinib, are able to achieve dramatic responses in a subset of patients. However, most patients treated with TKIs eventually develop resistance against these drugs. Here we review the physiology and pathology of EGFR activation in NSCLC, the clinical experience with TKIs, the mechanisms of resistance against TKIs, and discuss various approaches to treat resistance against TKIs.

Document emailed within 1 workday
Secure & encrypted payments

Li, J.; Hong, Q.; Zhang, X.; Hu, J.; Bai, C. 2014: Therapeutic efficacy and safety of chemotherapy subsequent EGFR-TKi in advanced non-small cell lung cancer patients with EGFR-TKi acquired resistance Zhonghua Yi Xue Za Zhi 94(30): 2342-2345
Shepherd, F.A. 2016: Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients Clinical Advances in Hematology and Oncology: H&o 14(1): 41-43
Cunningham, M.P.; Thomas, H.; Marks, C.; Green, M.; Fan, Z.; Modjtahedi, H. 2008: Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells International Journal of Oncology 33(5): 1107-1113
Takeda, K. 2009: Overcoming resistance to EGFR-TKi in lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(4): 552-556
Forde, P.M.; Ettinger, D.S. 2015: Managing acquired resistance in EGFR-mutated non-small cell lung cancer Clinical Advances in Hematology and Oncology: H&o 13(8): 528-532
Jin, B.; Zhang, Y.; Zhang, X.; Li, R.; Lou, Y.; Niu, Y.; Huang, A.; Han, B. 2014: Value of carcinoembryonic antigen levels in predicting the efficacy of EGFR-TKi in advanced non-small cell lung cancer harboring EGFR mutations Zhonghua Yi Xue Za Zhi 94(30): 2327-2331
Levy, B.P.; Rao, P.; Becker, D.J.; Becker, K. 2016: Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors Oncology 30(7): 601-612
Tonra, J.R.; Corcoran, E.; Deevi, D.S.; Steiner, P.; Kearney, J.; Li, H.; Ludwig, D.L.; Zhu, Z.; Witte, L.; Surguladze, D.; Hicklin, D.J. 2009: Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models Anticancer Research 29(6): 1999-2007
Urata, Y.; Satouchi, M. 2015: I. what is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer? Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(8): 931-934
Hirano, S.; Takeda, Y.; Hiraishi, Y.; Higashino, M.; Nakamichi, S.; Ishii, S.; Naka, G.; Iikura, M.; Izumi, S.; Sugiyama, H.; Kobayashi, N. 2012: Efficacy of combination therapy with EGFR-TKi and cytotoxic drug in lung adenocarcinoma already treated with EGFR-TKi Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(2): 213-219
Zhang, R.; Li, Y.; Chen, Y.; Liu, X.; Wang, Z.; Sun, H.; Zheng, Y.; Ding, Z.; Lan, L.; Li, M.; Qin, J.; Chen, X. 2015: Clinical implications of the concentration and EGFR/KRAS mutations of plasma cell free DNA of patients with lung cancer and esophageal cancer Zhonghua Yi Xue Za Zhi 95(47): 3839-3842
Dong, Q.-g.; Han, B.-h.; Huang, J.-s.; Yang, L.-m.; Huang, J.; Zhao, C.-y.; Lu, L.-q. 2006: Analysis of EGFR mutations in 176 cases of non-small cell lung cancer Zhonghua Zhong Liu Za Zhi 28(9): 686-690
Zhang, J.Q.; Xu, F.; Xu, X.L.; Zhou, H.C. 2017: Erlotinib in the treatment of small cell lung cancer with EGFR mutation: a case report Zhonghua Zhong Liu Za Zhi 39(9): 717-719
El Hamdani, W.; Amrani, M.; Attaleb, M.; Laantri, N.; Ennaji, M.M.; Khyatti, M.; El Mzibri, M. 2010: EGFR, p16INK4a and E-cadherin immuno-histochemistry and EGFR point mutations analyses in invasive cervical cancer specimens from Moroccan women Cellular and Molecular Biology 56 Suppl: Ol1373-Ol1384
Dahse, R.; Berndt, A.; Kosmehl, H. 2008: PCR-based testing for therapy-related EGFR mutations in patients with non-small cell lung cancer Anticancer Research 28(4b): 2265-2270
Saxena, A.; Nagasaka, M.; Li, Z.; Becker, D.J.; Levy, B.P. 2014: Double trouble: a case of concurrent de novo T790M and L858R EGFR mutations in treatment-naive advanced non-small-cell lung cancer Oncology 28(6): 526; 528 530, 534
Yang, B.; Zheng, D.; Zeng, Υa.; Qin, A.; Gao, J.; Yu, G. 2018: Circulating tumor cells predict prognosis following secondline AZD 9291 treatment in EGFR-T790M mutant non-small cell lung cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(4): 1077-1081
Li, Z.; Zhang, L-jun.; Wang, W-ping.; Guo, K.; Shao, J-yong.; Rong, T-hua. 2011: Correlation between EGFR gene mutation and high copy number and their association with the clinicopathological features in Chinese patients with non-small cell lung cancer Zhonghua Zhong Liu Za Zhi 33(9): 666-670
Shi, Y. 2015: The Guideline for Diagnosis and Treatment of Chinese Patients with sensitizing EGFR Mutation or ALK Fusion Gene-Positive Non-Small Cell Lung Cancer (2015 Version) Zhonghua Zhong Liu Za Zhi 37(10): 796-799
Lu, Z.; Song, Q.; Song, Q.; Jiang, S.; Yang, J.; Luo, F. 2010: Preparation of monoclonal antibody against lung cancer and identification of its targeting antigen Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 27(1): 147-151